Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marwan Fakih

Showing results (111-120 of 200) with videos related to

Pageof 20
Sort By:
Clinical Colorectal Cancer|January 16, 2025
Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT TrialJulien Taieb, Marwan Fakih, Josep Tabernero, et al.
Advances in Radiation Oncology|January 24, 2022
A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune ResponsesJoseph Chao, Ting-Fang He, Massimo D'Apuzzo, et al.
International Journal of Cancer|July 14, 2020
A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancerTakatoshi Matsuyama, Raju Kandimalla, Toshiaki Ishikawa, et al.
Annals of Surgical Oncology|December 3, 2024
ASO Visual Abstract: Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in Refractory Colorectal and Appendiceal Carcinomatosis-Secondary Analysis of the US PIPAC Collaborative Phase 1 TrialMuhammad Talha Waheed, Nora Ruel, Richard L Whelan, et al.
Annals of Surgical Oncology|September 13, 2024
Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in a Refractory Colorectal and Appendiceal Carcinomatosis: Secondary Analysis of the US PIPAC Collaborative Phase 1 TrialMuhammad Talha Waheed, Nora Ruel, Richard L Whelan, et al.
Frontiers in Oncology|January 31, 2025
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancerJulien Taieb, Marwan Fakih, Gabor Liposits, et al.
Current Treatment Options in Oncology|September 26, 2024
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal CancerThierry André, Eric Van Cutsem, Julien Taieb, et al.
JCI Insight|January 25, 2021
Potent antitumor effects of cell-penetrating peptides targeting STAT3 axisMaryam Aftabizadeh, Yi-Jia Li, Qianqian Zhao, et al.
Journal for Immunotherapy of Cancer|April 24, 2023
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)Marwan Fakih, Wael Harb, Daruka Mahadevan, et al.
Journal of Gastrointestinal Oncology|January 5, 2018
Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensusAndrew Kennedy, Daniel B Brown, Jonas Feilchenfeldt, et al.
Pageof 20

Showing results (111-120 of 200) with videos related to

Sort By:
Pageof 20
Clinical Colorectal Cancer|January 16, 2025
Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT TrialJulien Taieb, Marwan Fakih, Josep Tabernero, et al.
Advances in Radiation Oncology|January 24, 2022
A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune ResponsesJoseph Chao, Ting-Fang He, Massimo D'Apuzzo, et al.
International Journal of Cancer|July 14, 2020
A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancerTakatoshi Matsuyama, Raju Kandimalla, Toshiaki Ishikawa, et al.
Annals of Surgical Oncology|December 3, 2024
ASO Visual Abstract: Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in Refractory Colorectal and Appendiceal Carcinomatosis-Secondary Analysis of the US PIPAC Collaborative Phase 1 TrialMuhammad Talha Waheed, Nora Ruel, Richard L Whelan, et al.
Annals of Surgical Oncology|September 13, 2024
Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in a Refractory Colorectal and Appendiceal Carcinomatosis: Secondary Analysis of the US PIPAC Collaborative Phase 1 TrialMuhammad Talha Waheed, Nora Ruel, Richard L Whelan, et al.
Frontiers in Oncology|January 31, 2025
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancerJulien Taieb, Marwan Fakih, Gabor Liposits, et al.
Current Treatment Options in Oncology|September 26, 2024
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal CancerThierry André, Eric Van Cutsem, Julien Taieb, et al.
JCI Insight|January 25, 2021
Potent antitumor effects of cell-penetrating peptides targeting STAT3 axisMaryam Aftabizadeh, Yi-Jia Li, Qianqian Zhao, et al.
Journal for Immunotherapy of Cancer|April 24, 2023
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)Marwan Fakih, Wael Harb, Daruka Mahadevan, et al.
Journal of Gastrointestinal Oncology|January 5, 2018
Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensusAndrew Kennedy, Daniel B Brown, Jonas Feilchenfeldt, et al.
Pageof 20